- Generative chemistry plus synthesis planning
- Built specifically for drug discovery teams, not bolt-on AI
- Scales to organization-wide healthcare rollouts
Iktos
Generative chemistry and synthesis planning AI
SF7.4
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Bridge AI design and wet lab cyclesPharma and biotech chemistry teams
Bridge AI design and wet lab cyclesPharma and biotech chemistry teams
Best for
Pharma and biotech chemistry teams
Pricing
Custom
SoftFinders Score
7.4 / 10
Overview
What is Iktos?
Iktos is an AI drug discovery company for pharma and biotech chemistry teams, combining generative chemistry with synthesis planning.
- Research focus: It supports R&D acceleration and computational biology rather than guaranteed clinical outcomes, with candidates still requiring downstream validation and trials.
- Best-fit environment: Medicinal chemistry teams may benefit when generative design and synthesis planning align with discovery workflows.
- Engagement model: Access runs through pharma partnerships rather than self-service subscriptions, making data requirements, timelines to validated leads, and collaboration structure key considerations.
- Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, while buyers should confirm integration and review processes before adoption.
Iktos is best assessed as a partnership-led chemistry offering whose fit depends on objectives and workflow integration.
KEY FEATURES
What you get out of the box
Virtual Screening
Screens compound libraries against targets
Literature Intelligence
Mines biomedical literature for relevant evidence
Multi Omics
Integrates genomic and other omics data sources
Lab Integration
Connects discovery insights with wet-lab workflows
Partner Workflows
Workflows for pharma partner collaborations
Target Discovery
Identifies potential drug targets from biological data
USE CASES
Where teams put it to work
Bridge AI design and wet lab cycles
Identify drug targets from biology data
Accelerate molecule design cycles
Support protein engineering programs
Mine literature for research signals
Run virtual screens against targets
Editorial Take
What we like, and what to verify
- Engagement is partnership and software-led
- Drug success still depends on downstream trials
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Cradle SF 7.5
Why consider it
AI protein design for wet labs
Chai Discovery SF 7.3
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.7
Why consider it
Generative protein design across modalities
Causaly SF 7.6
Why consider it
Biomedical evidence and reasoning for R&D
Schrödinger SF 8
Why consider it
Physics-based and ML molecular simulation
FAQ